Latest Breaking News On - Frontier science foundation - Page 1 : comparemela.com

Frontier Science and QualityMetric Collaborate on Worldwide Treatment Study in Youth Living with HIV

/PRNewswire/ Frontier Science, the Data Management Center for the International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) Network, and.

Boston
Massachusetts
United-states
Botswana
South-africa
Michigan
Aspen-perry
Marlene-cooper
Vangie-lee
Data-management-center
International-maternal-pediatric-adolescent
National-institute-of-mental-health

Keeping HIV AIDS Clinical Trials Moving With Remote Source Review

Keeping HIV AIDS Clinical Trials Moving With Remote Source Review
clinicalleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from clinicalleader.com Daily Mail and Mail on Sunday newspapers.

Frontier-science-foundation
Science-foundation
Frontier-science

Roche's combination breast cancer treatment delivers positive results

Data from APHINITY study shows Roche’s Perjeta-based regimen reduces the risk of disease returning for people with HER2-positive early breast cancer - News - PharmaTimes

Germany
German
Levi-garraway
Institut-jules-bordet
Breast-international-group
Frontier-science-foundation
German-breast-group
Sibylle-loibl

F. Hoffmann-La Roche Ltd: Eight-year data from APHINITY study show Roche's Perjeta-based regimen continues to reduce the risk of disease returning for people with HER2-positive early breast cancer

Greatest benefit continued to be seen in people who are at a high risk of recurrence (those with lymph node-positive disease)With longer follow-up, treatment effect continues to be seen regardless of hormone

Germany
China
Japan
United-states
Scharl
Switzerland-general
Switzerland
American
German
Nathalie-meetz
Halozyme-enhanze
Levi-garraway

Eight-year data from APHINITY study show Roche's Perjeta-based regimen continues to reduce the risk of disease returning for people with HER2-positive early breast cancer

14.07.2022 - Greatest benefit continued to be seen in people who are at a high risk of recurrence (those with lymph node-positive disease)With longer follow-up, treatment effect continues to be seen regardless of hormone receptor status; however overall survival .

Germany
China
United-states
American
German
Levi-garraway
Institut-jules-bordet
Forschungs-gmb
American-society-of-clinical-oncology
St-gallen-international-breast-cancer-conference
Head-of-global-product-development
Breast-international-group